TPST

Tempest Therapeutics Inc

TPST, USA

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

https://www.tempesttx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TPST
stock
TPST

Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million Quiver Quantitative

Read more →
TPST
stock
TPST

Tempest Therapeutics Secures $4.25M in Direct Offering MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$9

Analyst Picks

Strong Buy

0

Buy

0

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

2.18

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-55.33 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.50 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.70

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 25.53% of the total shares of Tempest Therapeutics Inc

1.

Sabby Management LLC

(6.2292%)

since

2025/06/30

2.

Versant Venture Management LLC

(6.0757%)

since

2025/06/30

3.

TANG CAPITAL MANAGEMENT LLC

(3.1297%)

since

2025/06/30

4.

Vanguard Group Inc

(3.0316%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(2.3635%)

since

2025/07/31

6.

BlackRock Inc

(0.8799%)

since

2025/06/30

7.

Geode Capital Management, LLC

(0.7823%)

since

2025/06/30

8.

FMR Inc

(0.7483%)

since

2025/06/30

9.

Vanguard Institutional Extnd Mkt Idx Tr

(0.682%)

since

2025/07/31

10.

Fidelity Extended Market Index

(0.3797%)

since

2025/07/31

11.

UBS Group AG

(0.2528%)

since

2025/06/30

12.

Fidelity Total Market Index

(0.1698%)

since

2025/07/31

13.

Spartan Extended Market Index Pool F

(0.1049%)

since

2025/07/31

14.

Northern Trust Extended Eq Market Idx

(0.1021%)

since

2025/06/30

15.

NT Ext Equity Mkt Idx Fd - L

(0.1021%)

since

2025/06/30

16.

Fidelity Series Total Market Index

(0.0996%)

since

2025/07/31

17.

NT Ext Equity Mkt Idx Fd - NL

(0.0681%)

since

2025/06/30

18.

Extended Equity Market Fund K

(0.0607%)

since

2025/06/30

19.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0529%)

since

2025/06/30

20.

Morgan Stanley - Brokerage Accounts

(0.0475%)

since

2025/06/30

21.

Spartan Total Market Index Pool G

(0.0435%)

since

2025/07/31

22.

Advisor Group Holdings, Inc.

(0.0413%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0288%)

since

2025/06/30

24.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0243%)

since

2024/12/31

25.

Extended Equity Market Fund M

(0.0076%)

since

2025/06/30

27.

Atlantic Trust Group, LLC

(0.0059%)

since

2025/06/30

28.

Vanguard U.S. Eq Idx £ Acc

(0.0038%)

since

2025/07/31

29.

BNYM Mellon SL Market Completion UC1

(0.0014%)

since

2025/06/30

30.

Northern Trust Wilshire 5000

(0.0014%)

since

2025/06/30

31.

SBI Securities Co Ltd

(0.0013%)

since

2025/06/30

32.

Bank of America Corp

(0.0007%)

since

2025/06/30

33.

Parallel Advisors, LLC

(0.0004%)

since

2025/06/30

34.

BNP Paribas Arbitrage, SA

(0.0001%)

since

2025/06/30

35.

Blackstone Alternative Multi-Strategy I

(0.0001%)

since

2024/12/31

36.

SSgA U.S. Total Market Index Strategy

(0.0001%)

since

2025/03/31

37.

Jane Street Group LLC

(0%)

since

2025/03/31

38.

Tower Research Capital LLC

(0%)

since

2025/03/31

39.

Global Retirement Partners, LLC.

(0%)

since

2025/06/30

40.

Millennium Management LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.79

EPS Estimate

-0.2917

EPS Difference

-0.4983

Surprise Percent

-170.8262%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.